Cervical (HPV)

Test Shows Benefit for Detecting Women at Risk for Cervical Cancer

Results from the IMPACT trial demonstrate clear patient benefit in using Roche’s CINtec PLUS Cytology dual-stain biomarker technology.

Cervical (HPV)

Cervical Cancer Testing Tech Could Replace Pap Smears, Save Lives

Emerging techniques could help detect the virus leading to cervical cancer in low-income areas and developing nations.

Cervical (HPV)

HPV Test Misses Twice as Many Women Who Develop Cervical Cancer as Cotesting

Cotesting outperforms HPV or Pap testing alone in detecting cancer and precancer in women 30 years and older.

Reducing Cervical Cancer

Jun 14, 2019 | Cervical (HPV), Culture Media, Cytology

Some argue that cytology adds little to cervical screening efforts, prompting additional discussion on the contribution of cytology to screening protocols.

Screening Effectively Decreases Rare Cases of Cervical Cancer

May 27, 2019 | Cervical (HPV), Research

Women who participated in the screening program were less likely to develop adenosquamous and other rare types of cervical cancer.

Global Cloud-Based Cervical Cancer Screening Platform Launched

May 15, 2019 | Cervical (HPV), Cytology, Software

Wuhan University has joined with the Landing Med enterprise to create an international platform for Cloud-based cervical cancer screening.

Qiagen’s CareHPV Test Earns WHO Prequalification Status for Cervical Cancer Screening

Sep 24, 2018 | Cervical (HPV), Cytology

WHO prequalification recognizes the important role that the CareHPV test can have in screening women in emerging countries for HPV.

Cobas HPV Test Earns FDA Nod for Use with SurePath Preservative Fluid

Sep 24, 2018 | Cancer, Cervical (HPV), Culture Media, Molecular Diagnostics

The Roche test is approved for first-line screening with both SurePath preservative fluid and ThinPrep PreservCyt, the two most common collection media for Pap tests.

USPSTF Recommends Multiple Options for Screening Women for Cervical Cancer

Aug 23, 2018 | Cervical (HPV), Cytology

Women aged 21 to 65 benefit from screening, and the USPSTF recommends three strategies for screening women aged 30 to 65.

From the Editor: USPSTF Broadens HPV Testing Guidelines

Aug 22, 2018 | Cervical (HPV), Cytology

Guidelines on diagnostic testing issued by the United States Preventive Services Task Force...

Fast Track Diagnostics Releases PCR Kit for the Detection of 14 HPV High-Risk Subtypes

Apr 27, 2018 | Cervical (HPV), Cytology

Fast Track Diagnostics has expanded its comprehensive sexually transmitted infections portfolio by adding an array of human papillomavirus (HPV) tests.

Study Reveals Large Disparities in Survival for Patients with HPV-Associated Cancers

Dec 11, 2017 | Cervical (HPV), Research

A recent study has found large disparities in survival by sex, race, and age, among patients diagnosed with cancers caused by the human papillomavirus.

CETC Issues Urgent Call for Grassroots Comments on USPSTF Cervical Cancer Screening Recommendations

Oct 6, 2017 | Cancer, Cervical (HPV)

Consortium encourages pathologists and lab professionals to protect women’s health by supporting access to appropriate cervical cancer testing.

Leading Women’s Healthcare Groups Issue Joint Statement on USPSTF Recommendations

Oct 6, 2017 | Cancer, Cervical (HPV), Molecular Diagnostics, Womens Health

In spite of USPSTF recommendations, ACOG reaffirms its previous guidance in favor of cotesting with cytology and high-risk HPV testing for women aged 30–65 years.